Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva launches transdermal fentanyl in the US

This article was originally published in Scrip

Executive Summary

Teva Pharmaceutical Industrieshas received US FDA approval and started shipping its fentanyl transdermal patches, in 25, 50, 75 and 100 μg/hour doses, AB-rated generic versions of Ortho-McNeil's (J&J) Duragesic. Generic fentanyl patches are already available in the US from other companies, including Mylan, Watson, Lavipharm and Actavis. Earlier this year, lots of Watson's and Actavis's versions were separately adversely affected by manufacturing issues. Teva's version is manufactured by Aveva Drug Delivery Systems, a division of Nitto Denko, which Teva describes as one of the world's largest manufacturers of, and pioneer in, drug-in-adhesive transdermal patch technology.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC030931

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel